ONL1204
Phase 2Small molecule
ONL1204 is one of 77 small molecule programs targeting Glaucoma. It is currently in Phase 2.
4
Indications
5
Total Trials
1
Active Trials
76
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
237 competitors in Age-Related Macular Degeneration
#DrugCompanyPhaseTrials
1Lucentis
RochePhase 3
Eylea
RegeneronPhase 3
Vabysmo
RochePhase 3
Beovu
NovartisPhase 3
Macugen
PfizerPhase 3
Avastin
BBio-Thera Solutions
Phase 3
Retaane
AAlcon Research
Phase 3
Kenalog
BBausch Health Americas, Inc.
Phase 3
Forzinity
SStealth BioTherapeutics Inc.
Phase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Efficacy and Safety1 trial
Retinal Detachment1 trial
Age-Related Macular Degeneration1 trial
Glaucoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ONL1204. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- OONL Therapeutics